Core Laboratories Inc. CLB
8.95 USD -0.08 (-0.89%)
At closeNov 10, 2026, 4:01 PM EST
8.95 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
8.64 Day range 9.02
8.61 52-week range 20.36
- YTD
- -44.17%
- 1 year
- -42.11%
News
zacks.com CLB Q3 Earnings Miss Estimates on Higher Costs and Disruptions Core Laboratories' Q3 earnings missed estimates amid rising costs and geopolitical disruptions, despite a revenue beat and stronger international lab activity.
marketbeat.com Core Laboratories Q3 Earnings Call Highlights Core Laboratories NYSE: CLB reported higher third-quarter revenue, operating income and earnings per share from the prior quarter, while geopolitical disruptions in the Middle East and Russia-Ukraine…
seekingalpha.com Core Laboratories Inc. (CLB) Q3 2026 Earnings Call Transcript Core Laboratories Inc. ( CLB ) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Company Participants Lawrence Bruno - Chairman of the Board, CEO, President & COO Gwendolyn Schreffler - Senior Vice…
zacks.com Core Laboratories (CLB) Q3 Earnings Miss Estimates Core Laboratories (CLB) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.22 per share a year ago.
prnewswire.com CORE LAB REPORTS THIRD QUARTER 2026 RESULTS: REVENUE OF $ 132.1 MILLION, UP 6% SEQUENTIALLY AND DOWN 2% YEAR-OVER-YEAR OPERATING INCOME OF $ 12.1 MILLION; EX-ITEMS, $12.6 MILLION, UP 35% SEQUENTIALLY AND DOWN 24% YEAR-OVER-YEAR GAAP EARNINGS…
benzinga.com Core Laboratories Q3 Adj. EPS $0.16, Inline, Sales $132.077M Miss $132.143M Estimate Core Laboratories (NYSE:CLB) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is a 27.27 percent decrease over earnings of $0.22 per share from the same…
benzinga.com Core Laboratories Sees Q4 GAAP EPS $0.12-$0.20 vs $0.17 Est; Sees Sales $128.500M-$134.500M vs $133.317M Est Core Laboratories (NYSE:CLB) is looking for Q4 GAAP EPS of $0.12-$0.20 vs $0.17 analyst estimate. sees sales of $128.500 million-$134.500 million vs $133.317 million analyst estimate.
prnewswire.com CORE LABORATORIES ANNOUNCES TIMING OF THIRD QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL HOUSTON, Oct. 1, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its third quarter 2026 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m.
zacks.com CLB Declines 35% in the Past Six Months: How to Play the Stock? Core Laboratories' 35.1% six-month slide contrasts with stronger Production Enhancement trends and offshore recovery potential amid geopolitical risks.
benzinga.com Top 3 Energy Stocks You'll Regret Missing In September The most oversold stocks in the energy sector presents an opportunity to buy into undervalued companies.
benzinga.com Top 3 Energy Stocks You'll Regret Missing In September Oversold energy stocks may offer buying opportunities, with Baker Hughes, CNX Resources and Core Laboratories showing RSI readings below 30.
zacks.com 3 Oilfield Services Stocks Poised to Gain Despite Industry Challenges Strict capital discipline by upstream energy companies is acting as a dampener, making the outlook for the Zacks Oil and Gas-Field Services industry gloomy. FTI, OII and CLB are expected to survive…
defenseworld.net BlackRock Inc. Makes New Investment in Core Laboratories Inc. $CLB BlackRock Inc. acquired a new stake in Core Laboratories Inc. (NYSE: CLB) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The…
zacks.com Core Laboratories (CLB) Up 18.7% Since Last Earnings Report: Can It Continue? Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?
defenseworld.net Advisors Capital Management LLC Makes New $2.77 Million Investment in Core Laboratories Inc. $CLB Advisors Capital Management LLC purchased a new stake in Core Laboratories Inc. (NYSE: CLB) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased…
gurufocus.com John Rogers Buys Core Laboratories Inc (CLB) -- Shares Look 28% Undervalued on GF Value On June 30, 2026, John Rogers (Trades, Portfolio), founder of Ariel Investment, LLC, increased the firm's stake in Core Laboratories Inc (NYSE: CLB) by 904,557 s
zacks.com DTI or CLB: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Oil and Gas - Field Services sector might want to consider either Drilling Tools International Corp. (DTI) or Core Laboratories (CLB). But which of these two…
zacks.com Is CLB Stock Attractive After Its Sharp Selloff and Mixed Q2 Results? Core Laboratories stock looks cheaper after a 47.1% six-month selloff, but falling earnings and geopolitical pressure keep the near-term case cautious.
zacks.com Core Laboratories Q2 Earnings Beat Estimates, Decline Y/Y CLB's Q2 earnings top estimates despite lower revenues and profit as Production Enhancement strength offsets Reservoir Description weakness.
marketbeat.com Core Laboratories Q2 Earnings Call Highlights Core Laboratories NYSE: CLB reported second-quarter 2026 revenue of $124.6 million, up more than 2% from the prior quarter but down 4% from a year earlier, as stronger completion-product sales partly…
seekingalpha.com Core Laboratories Inc. (CLB) Q2 2026 Earnings Call Transcript Core Laboratories Inc. (CLB) Q2 2026 Earnings Call Transcript
zacks.com Core Laboratories (CLB) Q2 Earnings Surpass Estimates Core Laboratories (CLB) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.19 per share a year ago.- benzinga.com Core Laboratories Q2 Adj. EPS $0.11 Beats $0.09 Estimate, Sales $124.609M Miss $125.100M Estimate Core Laboratories (NYSE:CLB) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.09 by 22.22 percent. This is a 42.11 percent decrease over earnings of…
prnewswire.com CORE LAB REPORTS SECOND QUARTER 2026 RESULTS REVENUE OF $ 124.6 MILLION, UP 2% SEQUENTIALLY AND DOWN 4% YEAR-OVER-YEAR OPERATING INCOME OF $ 9.2 MILLION; EX-ITEMS, $9.4 MILLION, UP 42% SEQUENTIALLY AND DOWN 36% YEAR-OVER-YEAR GAAP EARNINGS PER…
benzinga.com Core Laboratories Sees Q3 GAAP EPS $0.12-$0.20 vs $0.16 Est; Sees Sales $128.500M-$135.500M vs $131.330M Est Core Laboratories (NYSE:CLB) is looking for Q3 GAAP EPS of $0.12-$0.20 vs $0.16 analyst estimate. sees sales of $128.500 million-$135.500 million vs $131.330 million analyst estimate.
benzinga.com Mobility Global To Replace Core Laboratories Effective Prior To The Opening Of Trading On Thursday, July 2 https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20260626-1484136/1484136_spgi-sem-5-6.pdf
benzinga.com Top 3 Energy Stocks That May Jump In Q2 Opportunity to buy undervalued energy stocks as RSI shows oversold levels. NCS Multistage, Core Laboratories, and Transportadora de Gas del Sur SA are major players with RSI near or below 30.
benzinga.com Core Laboratories Sees Q2 GAAP EPS $0.06-$0.12 vs $0.09 Est; Sees Sales $123.000M-$131.000M vs $127.900M Est Core Laboratories (NYSE:CLB) is looking for Q2 GAAP EPS of $0.06-$0.12 vs $0.09 analyst estimate. sees sales of $123.000 million-$131.000 million vs $127.900 million analyst estimate.- benzinga.com Core Laboratories Q1 Adj. EPS $0.06 Misses $0.11 Estimate, Sales $121.797M Miss $124.935M Estimate Core Laboratories (NYSE:CLB) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.11 by 45.45 percent. This is a 57.14 percent decrease over earnings of…
benzinga.com Earnings Scheduled For April 29, 2026 
benzinga.com Core Laboratories Sees Q1 Adj EPS $0.05-$0.07 vs $0.14 Est; Lowers Q1 Sales Guidance from $124.000M-$130.000M to $119.000M-$123.000M vs $128.290M Est Core Laboratories (NYSE:CLB) is looking for Q1 Adj EPS of $0.05-$0.07 vs $0.14 analyst estimate. Lowers Q1 sales outlook from $124.000 million-$130.000 million to $119.000 million-$123.000 million vs…- benzinga.com Core Laboratories Sees Q1 GAAP EPS $0.11-$0.15 vs $0.15 Est; Sees Sales $124.000M-$130.000M vs $128.290M Est Core Laboratories (NYSE:CLB) is looking for Q1 GAAP EPS of $0.11-$0.15 vs $0.15 analyst estimate. sees sales of $124.000 million-$130.000 million vs $128.290 million analyst estimate.
- benzinga.com Core Laboratories Q4 Adj. EPS $0.21 Beats $0.19 Estimate, Sales $138.255M Beat $131.100M Estimate Core Laboratories (NYSE:CLB) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.19 by 11.11 percent. This is a 4.55 percent decrease over earnings of $0.22…
- benzinga.com Earnings Scheduled For February 4, 2026
benzinga.com P/E Ratio Insights for Core Laboratories 
benzinga.com Las Vegas Sands Posts Upbeat Q3 Results, Joins Garrett Motion, LendingClub, Dow, Hexcel And Other Big Stocks Moving Higher On Thursday 
benzinga.com Earnings Scheduled For October 22, 2025 
benzinga.com A Preview Of Core Laboratories's Earnings 
benzinga.com Earnings Scheduled For July 23, 2025 - benzinga.com Core Laboratories's Earnings Outlook
- benzinga.com Stifel Maintains Hold on Core Laboratories, Lowers Price Target to $12 Stifel analyst Stephen Gengaro maintains Core Laboratories (NYSE:CLB) with a Hold and lowers the price target from $13 to $12.
- benzinga.com Citigroup Maintains Neutral on Core Laboratories, Lowers Price Target to $13 Citigroup analyst Scott Gruber maintains Core Laboratories (NYSE:CLB) with a Neutral and lowers the price target from $16 to $13.
benzinga.com Earnings Scheduled For April 23, 2025 - benzinga.com Earnings Scheduled For January 29, 2025
- benzinga.com Arm Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- benzinga.com Earnings Scheduled For January 31, 2024 Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion.
- benzinga.com Earnings Scheduled For November 1, 2023 Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.
- benzinga.com Earnings Scheduled For July 26, 2023 Companies Reporting Before The Bell • GSK (NYSE:GSK) is estimated to report quarterly earnings at $0.87 per share on revenue of $8.97 billion. • Stellantis (NYSE:STLA) is likely to report earnings…
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023
- benzinga.com Nasdaq, Methanex And Other Big Stocks Moving Lower On Monday U.S. stocks traded higher, with the Nasdaq Composite rising around 70 points on Monday. Here are some big stocks recording losses in today’s session. Beneficient (NASDAQ: BENF) shares fell 17% to…